Cronos Group Q1 2026 Update – CRON

Key Takeaways

• Q1 revenue rose 40% YoY to $45.2 million.
• Adjusted EBITDA surged 122% to $5.1 million, margin 11%.
• International revenue up 64%, Israel up 53% YoY.
• Share repurchases $17 million; $50 million authorization renewed.
• Spinach vape brand reached #1 market share in Canada.

Pulse Analysis

Cronos Group’s first‑quarter performance signals a turning point for the cash‑rich cannabis producer. Revenue jumped to $45.2 million, driven by a 45% increase in flower sales and a 33% rise in extracts, while adjusted EBITDA more than doubled, pushing the EV/EBITDA multiple down to roughly 16.7x. The company’s balance sheet, anchored by $822 million in cash and short‑term investments, enables aggressive capital deployment, including a $17 million share‑repurchase program and a renewed $50 million buy‑back authorization that supports earnings per share and price stability.

Geographic diversification is a key growth engine. International revenue climbed 64% YoY, with Israel delivering a 53% surge and other markets, notably Germany, expanding rapidly. The Spinach brand now commands a 9.8% share of the Canadian vape market and has taken the top spot, while its pre‑roll line, Spinach STIX, is positioned as the next major revenue driver. These product‑category gains offset modest pressure on gross margin, which slipped only one percentage point, illustrating effective cost management amid scaling operations.

Looking ahead, Cronos is betting on the GrowCo facility’s full throughput and the summer closing of the CanAdelaar acquisition to deepen its international footprint. Management’s guidance emphasizes sustainable revenue and EBITDA growth, reinforced by a stable relationship with Altria and a watchful eye on U.S. cannabis rescheduling. For investors, the combination of strong cash flow, disciplined buy‑backs, and expanding market share presents a compelling case for continued upside in a sector where liquidity is increasingly scarce.